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Abstract  Our  objective  was  to  evaluate  the  impact  of  using  an  imipenem
de-escalation  protocol  for  empiric  febrile  neutropenia  on  the  development  of  car-
bapenem  resistance.
A pre-post  intervention  design  was  used.  The  intervention  was  adopting  the
imipenem  de-escalation  approach,  which  began  on  January  1,  2012.  A  retrospec-
tive  chart  review  of  cases  of  febrile  neutropenia  bacteremia  was  performed  one
year  before  and  one  year  after  the  intervention.  We  compared  the  development  of
 between  the  two  study  periods.carbapenem  resistance
Seventy-ﬁve  episodes  of  febrile  neutropenia  bacteremia  were  included  in  the
study.  They  had  similar  demographics,  clinical  features  and  outcomes.  There  were  78
and  12  pathogens  in  the  primary  and  follow-up  blood  cultures,  respectively.  Approx-
imately  61%  and  66%  of  the  primary  and  follow-up  blood  cultures,  respectively,
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Introduction
Febrile  neutropenia  is  a  common  complication
during treatment  of  hematological  malignan-
cies and  hematopoietic  cell  transplant.  Several
antibiotics are  approved  as  an  empiric  therapy
for febrile  neutropenia  (cefepime,  piperacillin-
tazobactam,  meropenem,  and  imipenem)  [1,2].
The choice  of  antibiotic  therapy  for  febrile  neu-
tropenia varies  from  center  to  center  because
of the  local  epidemiology  of  bacterial  resistance
[1,2].  Multidrug-resistant,  gram  negative  bacteria
are becoming  increasingly  isolated  from  patients
with febrile  neutropenia  in  various  centers  world-
wide  [3].  In  centers  with  a  high  prevalence
of extended  beta-lactamase-producing  pathogens,
carbapenem  seems  to  be  a  reasonable  empiric
therapy for  febrile  neutropenia,  followed  by  a de-
escalation  approach.  This  approach  is  useful  to
prevent  mortalities  related  to  the  inappropriate
use of  empiric  antibiotics.  However,  surveillance  for
the development  of  multi-drug-resistant  pathogens
is recommended  when  adopting  this  approach
[4].  The  association  of  the  use  of  carbapenem
in patients  with  febrile  neutropenia  and  the
emergence of  carbapenem-resistant  gram-negative
bacteria has  not  been  fully  established.  According
to the  antibiogram  results  provided  by  our  micro-
biology laboratory,  there  is  a  60%  gram-negative
bacterial resistance  rate  to  piperacillin-tazobactam
and  Cefepime  in  the  hematology  unit  in  our
hospital. Before  January  2012,  no  clear  guide-
lines had  been  adopted  for  patients  with  empiric
febrile neutropenia.  Multiple  antibiotics,  including
ceftazidime,  cefepime,  piperacillin-tazobactam,
imipenem  and  meropenem,  were  used  based  on
physician  decision.  Since  January  2012,  we  have
adopted  a  new  policy,  which  is  the  use  of  car-
bapenem and  amikacin  as  the  initial  empiric
therapy for  febrile  neutropenic  patients  with
de-escalation to  piperacillin-tazobactam  in  the
a
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 with  similar  carbapenem  resistance  proﬁles  in  the  two
opulation,  57%  of  the  gram-negative  bacteria  were  ESBL
 the  gram-negative  bacteria  to  piperacillin/tazobactam
imipenem  (16%  versus  11%,  p  =  0.684),  and  meropenem
 not  signiﬁcantly  change  after  our  policy  change.
arbapenem  de-escalation  approach  for  febrile  neutrope-
 associated  with  an  increase  in  carbepenem  resistance.
nter  studies  are  recommended  to  further  conﬁrm  the
ziz  University  for  Health  Sciences.  Published  by  Elsevier
bsence  of  documented  extended  spectrum  beta-
actamase  producing  pathogens.
This study  aimed  to  determine  if  the  use  of
arbapenem for  febrile  neutropenia  in  our  hema-
ology center  was  associated  with  the  emergence
f bacterial  resistance,  especially  carbapenemase-
roducing, gram-negative  pathogens.
ethods
opulation
e  reviewed  the  data  provided  by  the  infec-
ion control  department  in  our  institution  for
ll patients  with  hematological  malignancies  and
ematopoietic  cell  transplantation  with  febrile
eutropenia  and  bacteremia  admitted  to  our  hospi-
al from  January  1,  2011,  until  December  31,  2012.
ll episodes  of  febrile  neutropenia  bacteremia  were
ncluded. Patients  with  multiple  episodes  of  febrile
eutropenia  bacteremia  were  also  included.
esign
 pre-post  intervention  design  was  used.  The  inter-
ention was  adopting  an  imipenem  de-escalation
pproach, which  began  on  January  1,  2012.  It
as achieved  by  changing  the  febrile  neutrope-
ia protocol,  educating  physicians  and  nurses  about
dherence to  the  protocol  and  auditing  the  com-
liance of  the  staff.  We  compared  the  data  from
wo different  time  periods.  The  ﬁrst  period  was
efore  our  policy  change  from  January  1,  2011,
ntil December  31,  2011,  during  which  there  were
o antibiotic  guidelines  for  febrile  neutropenia.  The
econd period  was  after  our  policy  change  and  the
doption  of  a de-escalation  approach  from  January
, 2012  until  December  31,  2012.  The  term  ini-
ial antibiotic  regimen  was  deﬁned  as  the  date  on
hich an  empiric  antibiotic  started  with  the  onset
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A de-escalation  protocol  for  febrile  neutropenia  ca
f  febrile  neutropenia  before  the  availability  of
lood culture  results.  The  term  modiﬁed  antibiotic
egimen was  deﬁned  as  the  deﬁnitive  antibiotics
sed based  on  the  results  of  the  blood  cultures.
he term  primary  blood  culture  was  deﬁned  as
he initial  blood  culture  performed  when  patients
eveloped febrile  neutropenia.  The  term  follow-up
lood culture  was  deﬁned  as  any  subsequent  blood
ulture  performed  while  the  patient  was  afebrile
nd neutropenic  to  assess  clearance  of  bacteremia.
dditional blood  cultures  were  also  performed  for
atients who  were  still  neutropenic  and  developed
reakthrough  fevers.
utcome assessment
e  used  BD  BACTEC  blood  culture  bottles  and  a
ITEK 2  Biomerieux  for  identiﬁcation  and  suscepti-
ility testing.  We  followed  the  CLSI  2012  guidelines
o determine  bacterial  sensitivities.  Multidrug  resis-
ant, gram-negative  pathogens,  per  the  National
ealthcare  Safety  Network  (NHSN)  manual,  include
cinetobacter  species  or  Pseudomonas  aeruginosa
hat are  resistant  to  at  least  one  member  of
t least  three  out  of  the  following  ﬁve  classes
f antibiotic  drugs:  penicillins,  cephalosporins,
minoglycosides,  ﬂuoroquinolones,  or carbapen-
ms. In  addition,  Klebsiella  species  resistant  to  at
east one  member  of  cephalosporins  or  carbapen-
ms, as  well  as  Escherichia  coli  resistant  to  at  least
ne member  of  carbapenems,  are  included  as  gram-
egative,  multidrug-resistant  organisms
tatistical methods
ata  are  presented  as  frequencies  and  percentages
or categorical  data  and  mean  ±  standard  devia-
ion (SD)  for  continuous  data.  The  resistance  rate
or a  speciﬁc  drug  was  calculated  by  dividing  the
rug-resistant  cultures  by  all  examined  cultures  for
hat drug.  Signiﬁcant  differences  between  the  two
tudy periods  (before  and  after  the  intervention)  in
emographic  characteristics,  diagnoses,  drug  resis-
ance, and  antimicrobial  use  were  examined  using
 chi-square  test  or  Fisher’s  exact  test  for  cat-
gorical data  and  Student’s  t-test  for  continuous
ata, as  appropriate.  All  p-values  were  two-tailed.
 values  <  0.05  were  considered  as  signiﬁcant.  SPSS
oftware  (release  21.0,  SPSS  Inc.,  Chicago,  U.S.)
as used  for  the  statistical  analyses.esults
eventy-ﬁve  episodes  of  febrile  neutropenia  bac-
eremia  were  included  in  the  study.  There  were
t
u
c
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8  and  12  pathogens  in  the  primary  and  follow-
p blood  cultures,  respectively.  Table  1  shows  the
emographic  and  clinical  characteristics  and  the
utcomes  of  the  patients.  The  majority  of  the
atients  (60%)  were  male,  and  the  average  age  was
9.2 ±  14.6  years.  The  average  absolute  neutrophil
ount was  0.119  ±  0.150  thousands  per  mm3.  The
ost common  diagnosis  was  leukemia  (56%),  fol-
owed by  lymphoma  (20%)  and  post-bone  marrow
ransplant  (19%).  Demographic  characteristics  and
iagnoses did  not  differ  signiﬁcantly  between  the
wo study  periods.  The  majority  of  the  patients  had
rimary bloodstream  infections  (72%)  and  hypoten-
ion (65%).  There  was  a  signiﬁcant  increase  in
rimary bloodstream  infections  (63%  versus  84%,
 =  0.039)  in  the  second  study  period  after  the
olicy change.  Approximately  36%  of  the  patients
equired  ICU  care,  and  crude  mortality  was  16%  dur-
ng the  study  with  no  difference  between  the  two
tudy  periods.
Gram-negative  microorganisms  were  the  most
ommon  microorganisms  detected  in  both  the
rimary  (48/78,  61.5%)  and  follow-up  (8/12,
6.7%) blood  cultures  (Table  2).  The  most  com-
on gram-negative  microorganisms  in the  primary
lood culture  were  E.  coli  (21.8%),  Klebsiella
pecies (14.1%),  and  P.  aeruginosa  (7.7%).  In
he follow-up  blood  culture,  they  were  Acine-
obacter species  (16.7%)  and  Stenotrophomonas
altophila  (16.7%).  The  most  common  gram  pos-
tive microorganisms  in  the  primary  blood  culture
ere  coagulase-negative  Staphylococci  (14.1%),
treptococcus  species  (9.0%),  and  Enterococcus
pecies (6.4%).  Enterococcus  species  were  the  most
ommon gram-positive  organisms  in  the  follow-up
lood  culture  (16.7%).  There  were  no  signiﬁcant  dif-
erences between  the  two  study  periods  in  the  type
f microorganisms  in  either  the  primary  (p  =  0.391)
r follow  up  (p  =  0.437)  cultures.
As  shown  in  Table  3, the  resistance  results  of
he gram-negative  microorganisms  in  the  primary
ultures  were  relatively  high  for  cephalosporins
71%) and  piperacillin/tazobactam  (65%)  but  rela-
ively low  for  carbapenems  (16%),  amikacin  (25%),
nd colistin  (13%).  The  resistance  to  carbapenem
emained the  same  in  the  two  study  periods
etween the  primary  blood  cultures.  The  per-
entage of  multidrug-resistant  and  ESBL-producing
ram-negative  microorganisms  were  similar  in  the
wo study  groups  in  the  primary  blood  cultures:
2% versus  20%  and  61%  versus  50%,  respectively.
s shown  in  Table  4, the  resistance  results  of
he gram-negative  microorganisms  in  the  follow-
p cultures  were  relatively  lower  than  the  primary
ulture, with  no  signiﬁcant  differences  between
he two  study  periods.  In  Fig.  1, we  show
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Table  1  Demographic  characteristics,  diagnoses,  and  clinical  outcomes  of  the  patients  with  episodes  of  febrile
neutropenia  bacteremia.
Before  policy
change
After  policy
change
Total  p-Value
Gender
Male  28  (65.1%)  17  (53.1%)  45  (60.0%)  0.294
Female  15  (34.9%)  15  (46.9%)  30  (40.0%)
Age
Mean  ±  SD 39.5  ±  13.9 38.8  ±  15.6 39.2 ±  14.6 0.844
<30  13  (30.2%) 13  (40.6%) 26  (34.7%) 0.652
30—59  26  (60.5%)  16  (50.0%)  42  (56.0%)
≥60  4  (9.3%)  3  (9.4%)  7  (9.3%)
ANC  (Mean  ±  SD)  0.123  ±  0.167  0.114  ±  0.127  0.119  ±  0.150  0.790
Diagnosis
Acute  lymphoblastic  leukemia  (ALL)  10  (23.3%)  8  (25.0%)  18  (24.0%)  0.767
Acute  myeloid  leukemia  (AML)  14  (32.6%)  9  (28.1%)  23  (30.7%)
chronic  myeloid  leukemia  (CML)  1  (2.3%)  0  (0.0%)  1  (1.3%)
Hodgkin  Lymphoma  2  (4.7%)  0  (0.0%)  2  (2.7%)
Non-Hodgkin  Lymphoma  3  (7.0%)  3  (9.4%)  6  (8.0%)
Burkitt  lymphoma  3  (7.0%)  3  (9.4%)  6  (8.0%)
Other  lymphomas  1  (2.3%)  0  (0.0%)  1  (1.3%)
Multiple  myeloma  2  (4.7%)  0  (0.0%)  2  (2.7%)
Myelodysplastic  Syndromes  (MDS)  1  (2.3%)  0  (0.0%)  1  (1.3%)
Aplastic  anemia  0  (0.0%)  1  (3.1%)  1  (1.3%)
Allogenic  BMT  2  (4.7%)  4  (12.5%)  6  (8.0%)
Autologous  BMT 4 (9.3%)  4  (12.5%)  8  (10.7%)
Bone  marrow  transplant  (BMT)
No  37  (86.0%)  24  (75.0%)  61  (81.3%)  0.225
Yes  6  (14.0%)  8  (25.0%)  14  (18.7%)
Hypotension
No  11  (25.6%) 15  (46.9%)  26  (34.7%)  0.055
Yes 32  (74.4%)  17  (53.1%)  49  (65.3%)
Primary  Blood  Stream  Infection  (BSI)
No  16  (37.2%) 5  (15.6%) 21  (28.0%)  0.039
Yes 27  (62.8%) 27  (84.4%) 54  (72.0%)
Transfer  to  Intensive  Care  Unit  (ICU)
No  25  (58.1%)  23  (71.9%)  48  (64.0%)  0.220
Yes  18  (41.9%)  9  (28.1%)  27  (36.0%)
Death
No  37  (86.0%)  26  (81.2%)  63  (84.0%)  0.575
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that  the  resistance  of  all  gram-negative  bacte-
ria to  piperacillin/tazobactam  (72%  versus  53%,
p =  0.161),  imipenem  (16%  versus  11%,  p  =  0.684),
and meropenem  (8%  versus  16%,  p  =  0.638)  did  not
signiﬁcantly  change  after  our  policy  change.
The most  commonly  used  initial  antimicrobial
agents were  carbapenems  (80%),  vancomycin  (67%),
and aminoglycosides  (61%).  Cephalosporins  were
not administered  (Table  5).  In  the  initial  treat-
ment, there  was  a  signiﬁcant  increase  in  the  use  of
imipenem  (51%  versus  88%,  p  =  0.001)  and  amikacin
(40% versus  81%,  p  < 0.001)  with  a  decreases  in
meropenem  use  (23%  versus  0%,  p  = 0.004)  in
the second  study  period  after  the  implementa-
tion of  the  guidelines.  In the  modiﬁed  treatment,
l
n
r
O6  (18.8%)  12  (16.0%)
iperacillin/tazobactam  use  increased  from  14%
o 38%  in  the  second  study  period  according  to
he policy  change  (p  = 0.018)  (Table  6). Meropenem
se also  decreased  signiﬁcantly  from  26%  to  3%
n the  modiﬁed  treatment  after  the  policy  change
p =  0.009).
iscussion
ur  study  showed  that  57%  and  27%  of  bacterial  iso-
ates among  patients  with  bacteremia  and  febrile
eutropenia  were  ESBL-producing  and  multidrug
esistant gram-negative  pathogens,  respectively.
ne reason  for  the  high  gram-negative  bacterial
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Table  2  Microorganisms  identiﬁed  from  the  primary  blood  cultures  of  the  episodes  of  febrile  neutropenia  bac-
teremia  before  and  after  the  policy  change  (total  number  of  pathogens  is  78).
Before  policy
change
After  policy
change
Total  p-value
Gram-positive  16  (35.6%)  12  (36.4%)  28  (35.9%)  0.391
Coagulase  negative  staphylococci  7  (15.6%)  4  (12.1%)  11  (14.1%)
Streptococcus  species  3  (6.7%)  4  (12.1%)  7  (9.0%)
Enterococcus  species  4  (8.9%)  1  (3.0%)  5  (6.4%)
Corynebacterium  species  2  (4.4%)  1  (3.0%)  3  (3.8%)
Other  gram-positive  organisms  0  (0.0%)  2  (6.1%)  2  (2.6%)
Gram-negative 29  (64.4%)  19  (57.6%)  48  (61.5%)
Escherichia  coli 11  (24.4%) 6  (18.2%)  17  (21.8%)
Klebsiella  spp. 7  (15.6%) 4  (12.1%) 11  (14.1%)
Pseudomonas  aeruginosa  3  (6.7%)  3  (9.1%)  6  (7.7%)
Stenotrophomonas  maltophila  4  (8.9%)  1  (3.0%)  5  (6.4%)
Acinetobacter  species  1  (2.2%)  2  (6.1%)  3  (3.8%)
Other  gram-negative  organisms 1  (2.2%)  3  (9.1%)  4  (5.1%)
Salmonella  species 2  (4.4%)  0  (0.0%)  2  (2.6%)
Candida  0  (0.0%) 2  (6.1%)  2  (2.6%)
Gram-negative  MDROa
No  15  (68.2%) 12  (80.0%)  27  (73.0%)  0.481
Yes 7  (31.8%) 3  (20.0%) 10  (27.0%)
ESBLb (E.  coli  and  Klebsiella)
No  7  (38.9%) 5  (50.0%)  12  (42.9%)  0.698
Yes 11  (61.1%) 5  (50.0%) 16  (57.1%)
a Gram-negative MDRO as per the NHSN manual include Acinetobacter species or Pseudomonas aeruginosa resistant to at least
one member of at least three of the following ﬁve classes: penicillins, cephalosporins, aminoglycosides, ﬂuoroquinolones, and
carbapenems. Klebsiella species resistant to at least one member of cephalosporins or carbapenems and Escherichia coli resistant
m-ne
r
t
b
tto at least one member of carbapenems are also included.
b ESBL is deﬁned as extended beta lactamase producers graesistance  in  our  institution  is  that  patients  are  ini-
ially admitted  to  other  hospitals  for  chemotherapy
efore being  referred  to  our  hospital  for  a  stem  cell
ransplantation.  The  prevalence  of  gram-negative
b
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Table  3  Resistance  of  microorganisms  identiﬁed  from  prim
nia  bacteremia  before  and  after  the  policy  change  (total  nu
Before  policy
change
Gram-negatives
Cephalosporina 20  (69.0%)  
Ceftriaxone  20  (69.0%)  
Ceftazidime  18  (62.1%)  
Cefepime  19  (65.5%)  
Piperacillin/tazobactam  21  (72.4%)  
Carbapenema 4  (16.0%)  
Imipenem  4  (16.0%)  
Meropenem  2  (8.0%)  
Amikacin  10  (34.5%)  
Colistin  5  (18.5%)  
Trimethoprim/sulfamethoxazole  13  (72.2%)  
Gram-positives
Vancomycin  2  (13.3%)  
Linezolid  0  (0.0%)  
a Resistance to any member of the class.gative pathogens.acterial  resistance  is  variable  between  different
enters. It  is  signiﬁcantly  higher  in  south  and  east
uropean  centers  compared  to  north  and  west  Euro-
ean centers  [5]. In  a  retrospective  Italian  study
ary  blood  cultures  among  episodes  of  febrile  neutrope-
mber  of  pathogens  is  78).
After  policy
change
Total  p-value
14  (73.7%)  34  (70.8%)  0.725
14  (73.7%)  34  (70.8%)  0.725
9  (47.4%)  27  (56.3%)  0.315
9  (47.4%)  28  (58.3%)  0.212
10  (52.6%)  31  (64.6%)  0.161
3  (15.8%)  7  (15.9%)  1.000
2  (10.5%)  6  (13.6%)  0.684
3  (15.8%)  5  (11.4%)  0.638
2  (10.5%)  12  (25.0%)  0.091
1  (5.3%)  6  (13.0%)  0.377
12  (66.7%)  25  (69.4%)  0.717
1  (8.3%)  3  (11.1%)  1.000
0  (0.0%)  0  (0.0%)  NA
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Table  4  Resistance  of  microorganisms  identiﬁed  from  follow-up  blood  cultures  among  episodes  of  febrile  neu-
tropenia  bacteremia  before  and  after  the  policy  change  (total  number  of  pathogens  is  12).
Before  policy
change
After  policy
change
Total  p-Value
Gram-negatives
Cephalosporina 1  (33.3%)  5  (100.0%)  6  (75.0%)  0.107
Ceftriaxone  1  (33.3%)  5  (100.0%)  6  (75.0%)  0.107
Ceftazidime  1  (33.3%)  3  (60.0%)  4  (50.0%)  1.000
Cefepime  1  (33.3%)  5  (100.0%)  6  (75.0%)  0.107
Piperacillin/tazobactam  2  (66.7%)  5  (100.0%)  7  (87.5%)  0.375
Carbapenema 2  (66.7%)  4  (80.0%)  6  (75.0%)  1.000
Imipenem  2  (66.7%) 4  (80.0%)  6  (75.0%)  1.000
Meropenem  0  (0.0%) 4  (80.0%) 4  (50.0%) 0.143
Amikacin  3  (100.0%)  3  (60.0%)  6  (75.0%)  0.464
Colistin  1  (50.0%)  2  (40.0%)  3  (42.9%)  1.000
Trimethoprim-sulfamethoxazole  —  —  —  NA
Gram-positives
Vancomycin 1  (33.3%)  0  (0.0%)  1  (33.3%)  NA
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from  2000  until  2007,  41%  of  E.  coli  bacteremia
cases were  caused  by  ESBL-producing  organisms  [6].
In another  retrospective  Korean  study  from  2010
until  2012,  27%  of  E.  coli  bacteremia  cases  were
due to  ESBL-producing  organisms  [7]. Both  stud-
ies had  similar  30-day  mortality  rates  (20%  and
22%, respectively).  The  presence  of  ESBL-producing
E. coli  bacteremia  was  a  signiﬁcant  predictor  of
mortality.  However,  inadequate  antibiotic  therapy
was a  risk  factor  for  mortality  in  the  Italian  study
but not  in  the  Korean  study  [6,7].When  evaluating  the  best  antibiotic  option  for
febrile neutropenia  in  our  center,  it  was  obvious
that choosing  cefepime  or  piperacillin/tazobactam
is inappropriate  due  to  their  59%  and  65%
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Figure  1  Resistance  of  the  gram  negative  bacteria  to  piperac
of  febrile  neutropenia  bacteremia  (total  number  of  pathogenesistance  rates,  respectively.  Our  de-escalation
ebrile neutropenia  protocol  of  imipenem  and
mikacin followed  by  piperacillin/tazobactam  was
ot associated  with  a  signiﬁcant  increase  in
arbapenem-resistant  pathogens.  Our  protocol
as useful  in  limiting  the  unnecessary  use  of
eropenem.  Though  not  statically  signiﬁcant,
he resistance  of  gram-negative  pathogens  to
iperacillin/tazobactam  was  reduced  with  our  pol-
cy change.  Based  on  the  European  guidelines  for
mpiric febrile  neutropenia  antibacterial  therapy,
t was  difﬁcult  to  determine  a  cutoff  prevalence
f resistance  at  which  a  unit  should  adopt  a  de-
scalation  approach  [4]. The  American  Hematology
ociety recommends  that  centers  with  more  than
8%11%
16%
ip enem Merop enem
illin/tazobactam  and  carbapenem  of  all  of  the  episodes
s  56).
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Table  5  Initial  treatment  among  episodes  of  febrile  neutropenia  bacteremia.
Before  policy
change
After  policy
change
Total  p-Value
Cephalosporinsa 0 (0.0%)  0  (0.0%)  0  (0.0%)  —
Ceftriaxone  0 (0.0%)  0  (0.0%)  0  (0.0%)  —
Ceftazidime  0 (0.0%) 0  (0.0%)  0  (0.0%)  —
Cefepime  0 (0.0%) 0  (0.0%) 0  (0.0%)  —
Piperacillin/tazobactam 10  (23.3%) 3  (9.4%) 13  (17.3%) 0.116
Carbapenemsa 32  (74.4%) 28  (87.5%) 60  (80.0%) 0.161
Imipenem  22  (51.2%)  28  (87.5%)  50  (66.7%)  0.001
Meropenem  10  (23.3%)  0  (0.0%)  10  (13.3%)  0.004
Aminoglycosidea 20  (46.5%)  26  (81.2%)  46  (61.3%)  0.002
Amikacin  17  (39.5%)  26  (81.2%)  43  (57.3%)  <0.001
Gentamicin  3 (7.0%)  0  (0.0%)  3  (4.0%)  0.256
Vancomycin  26  (60.5%)  24  (75.0%)  50  (66.7%)  0.187
Colistin  7 (16.3%)  2  (6.2%)  9  (12.0%)  0.286
Trimethoprim-sulfamethoxazole  1 (2.3%)  0  (0.0%)  1  (1.3%)  1.000
Linezolid  2 (4.7%)  0  (0.0%)  2  (2.7%)  0.504
Ciproﬂoxacin  1 (2.3%)  1  (3.1%)  2  (2.7%)  1.000
Tigecycline  2 (4.7%)  0  (0.0%)  2  (2.7%)  0.504
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0%  resistance  to  ESBL  pathogens  should  adopt  a
e-escalation  approach  [8].
Although our  patients  were  young,  most  of  them
ad severe  line-related  bacteremia  and  hypoten-
ion. The  mortality  and  ICU  admission  rate  were
imilar  before  and  after  adopting  a  de-escalation
pproach. The  rate  of  primary  bacteremia  and
ine-related infections  were  signiﬁcantly  higher
fter adopting  the  intervention.  It  is  crucial  for
ematology  centers  to  recognize  areas  where
w
s
i
Table  6  Modiﬁed  treatment  among  episodes  of  febrile  neu
Before  policy
change
Cephalosporinsa 5  (11.6%)  
Ceftriaxone  3  (7.0%)  
Ceftazidime  0  (0.0%)  
Cefepime  2  (4.7%)  
Piperacillin/tazobactam  6  (14.0%)  
Carbapenemsa 29  (67.4%)  
Imipenem  18  (41.9%)  
Meropenem  11  (25.6%)  
Aminoglycosidea 3  (7.0%)  
Amikacin  3  (7.0%)  
Gentamicin  0  (0.0%)  
Vancomycin  17  (39.5%)  
Colistin  9  (20.9%)  
Trimethoprim-sulfamethoxazole  4  (9.3%)  
Linezolid  5  (11.6%)  
Ciproﬂoxacin  3  (7.0%)  
Tigecycline  3  (7.0%)  
a Use of any member of the class.0  (0.0%)  1  (1.3%)  1.000
reventive  measures  should  be  applied  to  reduce
ram-negative bacterial  resistance  [4,8]. In  our
nstitution,  a multidisciplinary  team  was  developed
o reduce  the  rate  of  line-related  infections  in  the
ematology  unit.
With  the  increasing  rate  of  gram-negative
acterial  resistance  among  hematology  centers
orldwide, a de-escalation  approach  is  a  rea-
onable  approach  to  avoid  mortalities  related  to
nappropriate  empiric  antibiotic  therapy  in  patients
tropenia  bacteremia.
After  policy
change
Total  p-value
1  (3.1%)  6  (8.0%)  0.231
0  (0.0%)  3  (4.0%)  0.256
1  (3.1%)  1  (1.3%)  0.427
0  (0.0%)  2  (2.7%)  0.504
12  (37.5%)  18  (24.0%)  0.018
17  (53.1%)  46  (61.3%)  0.208
16  (50.0%)  34  (45.3%)  0.484
1  (3.1%)  12  (16.0%)  0.009
1  (3.1%)  4  (5.3%)  0.632
1  (3.1%)  4  (5.3%)  0.632
0  (0.0%)  0  (0.0%)  —
11  (34.4%)  28  (37.3%)  0.648
9  (28.1%)  18  (24.0%)  0.471
2  (6.2%)  6  (8.0%)  0.696
1  (3.1%)  6  (8.0%)  0.231
0  (0.0%)  3  (4.0%)  0.256
2  (6.2%)  5  (6.7%)  1.000
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with  febrile  neutropenia.  In  an  Italian  center,  33%
of bloodstream  infections  were  due  to  multi-drug-
resistant Pseudomonas  species.  The  mortality  rate
among cases  that  received  inadequate  therapy
was 83%  [9].  In  a  New  York  Center,  patients  with
febrile  neutropenia  developed  bacteremia  due  to
carbapenem-resistant  Enterobacteriaceae  in  the
absence of  exposure  to  carbapenems.  Evidently,
85% of  patients  did  not  receive  appropriate  antibi-
otics.  The  mortality  was  69%  and  20%  in  neutropenic
and non-neutropenic  patients,  respectively  [10].
When adopting  a  de-escalation  approach,  con-
tinuous  surveillance  for  gram  negative  resistance
is recommended.  In  a  prospective  epidemiolog-
ical study  from  1995  to  2008  in  Belgium,  the
use of  cefepime  and  amikacin  in  patients  with
febrile  neutropenia  was  not  associated  with  sig-
niﬁcant  development  of  cefepime  or  amikacin
resistance among  gram-negative  pathogens.  This
study included  surveillance  cultures  and  cultures  of
documented  infections  [11].  However,  in  another
study conducted  in  Israel  among  patients  with
documented gram-negative  infections,  the  antibi-
otic resistance  was  higher  in  subsequent  infections
compared to  initial  infections.  The  resistance  to
piperacillin/tazobactam  increased  from  14%  to
60% (p  <  0.001)  from  the  initial  to  the  subsequent
infection, respectively.  Similarly  the  resistance  to
meropenem  increased  from  5%  to  24%  (p  < 0.004)
[12].  It  is  unknown  whether  combining  aminoglyco-
sides to  the  initial  antibacterial  therapy  could  have
prevented  resistance  in  the  subsequent  infection.
Adherence to  the  antimicrobial  stewardship  pro-
gram was  associated  with  a  higher  survival  rate  in
patients with  febrile  neutropenia  in  Brazil.  During
this study,  cefepime  was  the  recommended  empiric
antibiotic  for  cases  of  febrile  neutropenia.  The
extent of  bacterial  resistance  is  not  known  in  the
institution  [13].
Our  pilot  study  was  limited  by  its  small  sam-
ple size  and  retrospective  nature.  In  addition,
the time  of  data  analysis  was  too  short  to  doc-
ument bacterial  resistance  after  the  application
of the  de-escalation  approach.  It  was  not  possible
to increase  the  sample  size  because  all  eligi-
ble patients  from  our  center  were  included  in
the study.  Future  multicenter  prospective  studies
are warranted.  We  acknowledge  that  our  study
is too  under-powered  to  detect  small  difference
in carbapenem  resistance  between  the  two  study
periods.  However,  the  power  analysis  indicates  that
our sample  had  enough  power  to  detect  25—30%
differences in  resistance  before  and  after  the  inter-
vention. Although  the  retrospective  nature  of  the
quasi-experimental  design  used  in  the  current  study
is limited  in  establishing  causality,  it  is frequentlyA.  Alshukairi  et  al.
sed  in  the  area  of  antimicrobial  resistance  where
andomization  is  unethical  or  non-feasible  [14].
onclusion
n  the  era  of  increasing  incidence  of  ESBL-producing
nd carbapenem-resistant,  gram-negative  bacteria
orldwide,  choosing  an  empiric  antibacterial  ther-
py for  febrile  neutropenia  is  a  real  challenge  in
arious institutions.  Future  prospective  multicen-
er studies  evaluating  de-escalation  protocols  for
mipenem  and  amikacin  are  required  to  reduce
ebrile neutropenia  mortality  without  the  develop-
ent  of  bacterial  resistance.
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